An interventional study of Withania somnifera and Active comparator in Polyendocrine Metabolic Ovarian Syndrome, Stress and Polycystic Ovarian Syndrome (PCOS), sponsored by Medical University of Lodz. Completed at 1 site in Poland. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-08-06.
Sponsored by Medical University of Lodz · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Polycystic Ovary Syndrome with a site in Poland — 5 open to participants now, 6 under way, none of them phase 3. Polycystic Ovary Syndrome · Poland.
Among the 18 studies in Polycystic Ovary Syndrome with a site in Poland, this one is the 11th largest by enrollment of the 11 interventional ones that give a count, is one of 5 that started in 2025, is one of 9 with no phase, and was the 18th registered.
958 studies on the registry are indexed under Polycystic Ovary Syndrome; 175 are open to participants now.
Browse Polycystic Ovary Syndrome studies →5 of the 18 studies in Polycystic Ovary Syndrome with a site in Poland are open now. Recruiting first, the newest first:
Poznan University of Physical Education · Sites in Poland
Ages 18–90 · Healthy volunteers
Jagiellonian University · Sites in Poland
Ages 18–45 · Women only · Healthy volunteers
Jagiellonian University · Sites in Poland
Ages 18–45 · Women only · Healthy volunteers
Jagiellonian University · Sites in Poland
Ages 18–45 · Women only · Healthy volunteers
Joanna Bajerska · Sites in Poland
Ages 18–40 · Women only
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 119 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 105 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 70 across 699 interventional studies indexed under Polycystic Ovary Syndrome.
Median enrollment 80 across the 11 interventional studies, 100 across the 5 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 18 has an industry lead sponsor. The 8 most frequent:
Medical University of Lodz is the lead sponsor of 107 studies on the registry; 10 are open to participants now.
Medical University of Lodz has 1 study filed under Polycystic Ovary Syndrome — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Polycystic Ovary Syndrome with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to ascertain the impact of a standardized Withania somnifera extract on endocrine, metabolic, and psychometric parameters in women diagnosed with polyendocrine metabolic ovarian syndrome. The assessment will encompass a range of parameters to determine the severity of depression, stress levels, the quality of sleep, blood pressure, body mass index, and body composition. Additionally, biochemical, metabolic, and endocrine blood parameters in serum will be analysed.
The trial's findings may yield a safe and easy-to-use method of adjunctive treatment that could complement therapy in patients with polycystic ovary syndrome.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Withania somnifera, cholecalciferol, folic acid, and 5-methyltetrahydrofolate
Dietary Supplement: Withania somnifera
Cholecalciferol, folic acid, and 5-methyltetrahydrofolate
Dietary Supplement: Active comparator
Drug pages: Withanolide DStudies of Withanolide DWithanolide D pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · AshwagandhaStudies of AshwagandhaAshwagandha pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Withania somnifera (10 mg of withanolides), cholecalciferol (2000 IU), folic acid (0.4 mg), and 5-methyltetrahydrofolate (0.4 mg) orally once daily
Cholecalciferol (2000 IU), folic acid (0.4 mg), and 5-methyltetrahydrofolate (0.4 mg) orally once daily
Beck Depression Inventory (BDI-II)
The Beck Depression Inventory (BDI-II) is a validated 21-item questionnaire assessing symptoms of depression. It includes 21 items, each containing four options, scored on a scale of 0 to 3, where 0 indicates the absence of a symptom and 3 its greatest intensity. Higher scores indicate greater symptom severity (worse outcome). This outcome measures the mean change from baseline in BDI-II total score, where a reduction in score indicates improvement in psychological symptoms.
Time frame: Baseline, 3 months, 6 months
Perceived Stress Scale (PSS-10)
The Perceived Stress Scale (PSS-10) is a validated 10-item self-reported questionnaire that measures perceived stress over the previous month. Each item is scored from 0 (never) to 4 (very often). The total score ranges from 0 to 40, with higher scores indicating greater perceived stress (worse outcome). This outcome measures the mean change from baseline in PSS-10 total score, where a reduction in score indicates improvement in perceived stress.
Time frame: Baseline, 3 months, 6 months
Pittsburgh Sleep Quality Index (PSQI)
The Pittsburgh Sleep Quality Index (PSQI) is a validated questionnaire assessing subjective sleep quality and disturbances over the previous month. The global score ranges from 0 to 21, with higher scores indicating poorer sleep quality (worse outcome). This outcome measures the mean change from baseline in PSQI global score, where a reduction in score indicates improvement in sleep quality.
Time frame: Baseline, 3 months, 6 months
International Physical Activity Questionnaire - Short Form (IPAQ-SH)
The IPAQ-SH (International Physical Activity Questionnaire - Short Form) is a brief, standardised tool used to assess physical activity over the last 7 days. It captures time spent in walking, moderate activity, vigorous activity, and sitting, allowing researchers to calculate weekly energy expenditure in MET-minutes.
Time frame: Baseline, 3 months, 6 months
Food Frequency Questionnaire (FFQ-6)
The FFQ-6 (Food Frequency Questionnaire - 6-category, 62-item version) is a non-quantitative dietary assessment tool widely used in Polish nutritional research. It records the habitual frequency of consumption of 62 food items across six predefined categories, enabling the identification of dietary patterns.
Time frame: Baseline, 3 months, 6 months
Complete blood count parameters: white blood cell count (WBC), red blood cell count (RBC), haemoglobin, haematocrit, and platelets concentration
The following parameters were analysed to evaluate changes over time within and between treatment groups.
Time frame: Baseline, 3 months, 6 months
Concentration of metabolic and inflammatory parameters: fasting glucose, fasting insulin, C-reactive protein (CRP), total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides (TG), and alanine aminotransferase (ALT) blood concentration
The following parameters were analysed to evaluate changes over time within and between treatment groups.
Time frame: Baseline, 3 months, 6 months
Concentration of endocrine parameters: total testosterone, prolactin, oestrogen, sex hormone-binding globulin (SHBG), luteinising hormone (LH), follicle-stimulating hormone (FSH), cortisol, and dehydroepiandrosterone sulphate (DHEA-S) blood concentration
The following parameters were analysed to evaluate changes over time within and between treatment groups.
Time frame: Baseline, 3 months, 6 months
Blood pressure parameters: systolic (SBP) and diastolic (DBP) blood pressure
Blood pressure was measured by a sphygmomanometer.
Time frame: Baseline, 3 months, 6 months
Body composition: skeletal muscle mass, and fat mass
The assessment of body composition was conducted through the utilisation of Bioelectrical Impedance Analysis (BIA).
Time frame: Baseline, 3 months, 6 months
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Jan 2025 to primary completion in Nov 2025, 10 months.
Of 204 non-industry interventional studies with no phase under Polycystic Ovary Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's 10 months is below that.
Counting every sponsor, half of 219 studies reached it within 18 months; a quarter within 7 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Withanolide D · Ashwagandha